The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder.
Ontology highlight
ABSTRACT: Bumetanide, a drug being studied in autism spectrum disorder (ASD) may act to restore gamma-aminobutyric acid (GABA) function, which may be modulated by the immune system. However, the interaction between bumetanide and the immune system remains unclear. Seventy-nine children with ASD were analysed from a longitudinal sample for a 3-month treatment of bumetanide. The covariation between symptom improvements and cytokine changes was calculated and validated by sparse canonical correlation analysis. Response patterns to bumetanide were revealed by clustering analysis. Five classifiers were used to test whether including the baseline information of cytokines could improve the prediction of the response patterns using an independent test sample. An immuno-behavioural covariation was identified
SUBMITTER: Li Q
PROVIDER: S-EPMC9166783 | biostudies-literature | 2022 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA